Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetyl-Cysteine + Methadone for Opioid Retention
NCT01047956Phase 4Unknown
- Sponsor
- Taichung Veterans General Hospital
- Start
- Jun 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of acetylcysteine in opioid use disorder (OUD), sponsored by Taichung Veterans General Hospital. Primary endpoint: Retention Rate at 6 months. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01047956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01047956.